PDCD1 and neoplasm: Notably, co-delivery of celecoxib and anti-PD-1 monoclonal antibodies increased the numbers of INF-γ-expressing CD4+ and CD8+ T cells and decreased the numbers of intratumoral Tregs, MDSCs, and PD-L1-positive tumor cells.